MarketPulse
D

$DSGN

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Design Therapeutics Reports Positive Four-Week Data for Friedreich Ataxia Treatment

Design Therapeutics announces positive Phase 1/2 data for DT-216P2 showing clinical improvements and biomarker activity in Friedreich ataxia patients.
DSGNclinical trialgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Design Therapeutics to Unveil RESTORE-FA Trial Data for Friedreich's Ataxia Treatment

Design Therapeutics will present Phase 1/2 data for DT-216P2, its experimental Friedreich's ataxia treatment, on May 18, 2026.
DSGNgene therapyFriedreich's ataxia